Market opportunity


A woman in a lab sitting down with some test tubes

Pain therapy market » Market opportunity

Targeting a large market with high growth

Among the worldwide adult population, up to 10 percent of people are said to be suffering from neuropathic pain at any one time.

The Global Pain Management Therapeutics Market is expected to grow to 77.3 billion EUR in 2025. North America accounts for the largest market share (approx. 40%) followed by Europe (approx. 26%)1. The growth is driven by, among other things, aging populations with increasing prevalence of chronic disorders and favourable healthcare reforms.

The global market for neuropathic pain was valued at around EUR 7 billion in 2022 and is expected to reach over EUR 13 billion by 20332. Market growth is driven by an aging global population with increasing incidences of diseases that can cause nerve pain, including type 2 diabetes, cancer, and shingles. Other drivers include greater awareness of nerve pain among doctors as well as patients. The company’s primary indications – allodynia and hyperalgesia – affect about twenty-five per cent of people suffering from nerve pain

Market growth is driven by an ageing global population with an increasing prevalence  of diseases that can cause neuropathic pain, including type 2- diabetes, cancer and shingles. Other driving forces are increased knowledge of neuropathic pain in both doctors and patients. The company's first indication is neuropathic pain characterized by allodynia , (pain produced by a normally innocuous stimulus) (extreme sensitivity to pain), which affects approximately 25% of neuropathic pain patients.

PharmNovo also sees clinical potential for PN6047 in other areas, such as post-surgical and cancer pain, migraine, pruritus (itch) and chronic cough.

Also addresses mood disorders

PharmNovo’s drug candidate PN6047 also addresses an associated problem: neuropathic pain patients frequently suffer from anxiety and depression, which exacerbates their pain and generates a vicious cycle of low mood and increasing pain. DOR agonists can attenuate both pain and the associated emotional disorders. which will have enormous market potential.

If PharmNovo’s DOR agonist PN6047 can attenuate pain and the associated emotional disorders, it will have enormous market potential. A new neuropathic pain medicine such as PN6047 would aid patients’ return to work, increase efficacy and reduce direct health service costs.

1 ZION Market Research. Global Pain Management Therapeutics Market 2016-2025.



  • Treatment of chronic pain is still a clearly unmet medical need.

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more